The U.S. Acellular Dermal Matrices Market is estimated to be valued at US$ 2783.32 Mn in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Acellular dermal matrices are used in reconstructive and plastic surgery procedures for soft tissue reconstruction and reinforcement. They are used in breast reconstruction, abdominal wall reconstruction, burn reconstruction, flexor tendon repair and hernia repair. They provide strength, support natural healing and prevent complications. They are made from donated human or pig skin that is processed to remove cells and potentially infectious factors while maintaining the natural collagen structure and tissue integrity.
Market Dynamics:-
The U.S. acellular dermal matrices market is expected to be driven by the growing geriatric population and subsequent increase in soft tissue reconstruction procedures. According to the U.S. Census Bureau, by 2030, all baby boomers will be older than 65 years and one in five US residents will be retirement age. This strong growth will result in higher incidence of conditions like hernias, that require soft tissue reconstruction. Furthermore, increasing awareness about advanced soft tissue reconstruction options and favorable reimbursement for acellular dermal matrices in the U.S. also contributes to the market growth. However, high costs of acellular dermal matrices and ethical issues related to xenogeneic or allogenic tissues may hamper the market growth.
Segment Analysis:-
The U.S. acellular dermal matrices market is dominated by the synthetic sub-segment due to its versatility and low immunogenic reaction rate compared to allografts and autografts. Synthetic acellular dermal matrices provide desired structural support while allowing tissue ingrowth and epithelialization.
PEST Analysis:-

• Political: The market is favorably impacted by initiatives supporting research in regenerative medicine and wound care therapies.
• Economic: Rising healthcare expenditure in the U.S. and availability of reimbursement for procedures utilizing ADMs are driving market growth.
• Social: Increasing incidence of breast reconstruction surgeries and growth in elderly population who are prone to injuries and chronic wounds boost demand.
• Technological: Developments in biomaterial science facilitating production of acellular dermal matrices with improved biocompatibility and reduced risk of immune rejection.

Key Takeaways:-
The U.S. Acellular Dermal Matrices Market Demand is expected to witness a CAGR of 3.8% over 2023-2030, reaching a value of US$ 3,892.56 Mn in 2030 driven by the increasing prevalence of breast reconstruction procedures and burns & chronic wounds. The South region is projected to dominate the market through 2030 owing to higher focus on research and presence of key players.
Key players operating in the U.S. acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc.
 
Read More - https://www.newsstatix.com/u-s-acellular-dermal-matrices-market-demand-and-share-analysis/